Efficacy of Transcatheter Arterial Embolization in Managing Rectus Sheath Hematoma: A Tertiary Single Center Results
Haseki Tip Bulteni, cilt.63, sa.2, ss.112-118, 2025 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 63 Sayı: 2
- Basım Tarihi: 2025
- Doi Numarası: 10.4274/haseki.galenos.2025.62207
- Dergi Adı: Haseki Tip Bulteni
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.112-118
- Anahtar Kelimeler: Rectus sheath hematoma, interventional radiology, embolization, epigastric artery
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Rectus sheath hematoma (RSH) is a rare but potentially life-threatening condition. This study aimed to evaluate the effectiveness of transcatheter arterial embolization (TAE) in the management of RSH by analyzing imaging features, embolization techniques, and clinical outcomes. Methods: In this retrospective observational study, 22 patients with RSH who underwent TAE between June 2020 and June 2023 were included. Etiological factors, hematoma classification, angiographic findings, embolization materials, and clinical outcomes were analyzed. Laboratory values and transfusion requirements were compared before and after the procedure. Results: The most common etiology was anticoagulation therapy (50%), followed by trauma (13.6%) and post-abdominal surgery (13.6%). A bleeding source was identified in 36.3% of patients on computed tomography angiography and 45.4% on digital subtraction angiography. Technical success was 100%, and clinical success was 90.9%. Post-embolization, transfusion requirements decreased significantly (p<0.05). Hemoglobin and hematocrit levels increased by 17.2% (p=0.004) and 20.7% (p=0.001), respectively. No significant difference was observed between Type 2 and Type 3 hematomas in terms of clinical and procedural outcomes. Conclusion: TAE is a safe and highly effective treatment for RSH, leading to significant hemodynamic stabilization and reduced transfusion requirements. It should be considered a primary treatment option in patients with moderate to severe RSH, particularly those who are hemodynamically unstable.